Court Grants Teva-Ivax Bid For Zocor Exclusivity

Law360, New York (May 1, 2006, 12:00 AM EDT) -- In a boon for Israeli generics maker Teva Pharmaceuticals Ltd., a federal court has ruled that its recent acquisition, Ivax Corp., should be granted 180 days of exclusivity to market a generic version of Merck & Co.’s blockbuster cholesterol drug Zocor.

Teva confirmed on Monday that it had been granted summary judgment by the U.S. District Court for the District of Columbia, triggering hopes that Ivax will finally win exclusivity following a six-year crusade to sell generic Zocor.

The development serves as welcome news for Teva,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.